公开(公告)号：US12208130B2

公开(公告)日：2025-01-28

申请号：US16490228

申请日：2018-03-14

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ DE LILLE ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE

Inventor： Paolo Giacobini ,  Vincent Prevot

IPC: A61K38/09 ,  A61K31/7105 ,  A61K45/06

Abstract: The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use to rescue ovulation and fertility in postpuberal PCOS affected individuals.

公开(公告)号：US12060301B2

公开(公告)日：2024-08-13

申请号：US16956132

申请日：2018-12-21

Applicant: THALES ,  UNIVERSITÉ DE LILLE ,  NANYANG TECHNOLOGICAL UNIVERSITY ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Matthieu Pawlik ,  Edwin Hang Tong Teo ,  Philippe Coquet

IPC: C04B35/583 ,  C04B38/00 ,  C04B41/45 ,  C04B41/53 ,  C04B41/82 ,  C04B41/85 ,  F28D20/02 ,  H01L23/427

CPC classification number: C04B35/583 ,  C04B38/0003 ,  C04B41/4535 ,  C04B41/5353 ,  C04B41/82 ,  C04B41/85 ,  H01L23/427 ,  C04B2237/086 ,  F28D20/023

Abstract: The invention relates to a composite material based on boron nitride (BN(C)) in the form of a continuous structure; and a phase change material (PCM) incorporated within said continuous BN(C) structure and is embedded within a polymer layer, a process for manufacturing same, and the components that comprise same.

公开(公告)号：US11761884B2

公开(公告)日：2023-09-19

申请号：US17310242

申请日：2020-01-27

Applicant: UNIVERSITEIT GENT ,  IMEC VZW ,  VMICRO SAS ,  CNRS ,  ISEN YNCRÉA HAUTS-DE-FRANCE ,  UNIVERSITÉ DE LILLE ,  ECOLE CENTRALE DE LILLE ,  UNIVERSITÉ POLYTECHNIQUE HAUTS-DE-FRANCE

Inventor： Bart Kuyken ,  Mathias Vanwolleghem ,  Mattias Verstuyft ,  Benjamin Walter ,  Jean-Francois Lampin

IPC: G01N21/17

CPC classification number: G01N21/1702 ,  G01N2021/1704 ,  G01N2201/06113

Abstract: An integrated photoacoustic transducer, sensing system and method for assisting in sensing a concentration of a species in a fluid such that the integrated photoacoustic transducer includes a waveguide structure. The waveguide structure has an optical resonance spectrally overlapping a spectral absorption line or band of the species. The photoacoustic transducer includes at least one acoustic cavity formed in a portion of the waveguide structure and configured for receiving the fluid for sensing comprising the species. The at least one acoustic cavity has an acoustic resonance spectrally overlapping with a harmonic of a modulation frequency. At least one acoustic transducer comprising a deformable mechanical portion is included in the photoacoustic transducer. The deformable mechanical portion is in direct acoustic communication with the at least one acoustic cavity and has an adjustable mechanical resonance, which can be brought into spectral overlap with an acoustic resonance of the least one acoustic cavity.

公开(公告)号：US20230075405A1

公开(公告)日：2023-03-09

申请号：US17795754

申请日：2021-01-29

Applicant: HAP2U ,  UNIVERSITÉ DE LILLE

Inventor： Matthieu RUPIN ,  Pierre GARCIA ,  Frederic GIRAUD ,  Christophe GIRAUD-AUDINE ,  Betty SEMAIL ,  Michel AMBERG

IPC: G06F3/01 ,  G06F3/041

Abstract: The invention relates to a touch interface comprising, on the one hand, an interfacial surface able to generate a haptic-feedback effect in response to a touch of said surface by a user, and, on the other hand, at least one piezoelectric actuator configured to generate, in said interfacial surface, at least one wave of ultrasonic frequency able to endow the particles of this surface with an elliptical movement having a movement component tangential to said surface, which component is denoted ut(t), and a movement component normal to said surface, which component is denoted un(t), wherein said wave of ultrasonic frequency is chosen so that the amplitude Ut of the tangential component ut(t) and the amplitude Un of the normal component un(t) are substantially equal.

公开(公告)号：US20220026381A1

公开(公告)日：2022-01-27

申请号：US17297128

申请日：2019-11-26

Applicant: TOTAL MARKETING SERVICES ,  Centre national de la recherche scientifique ,  Université de Lille

Inventor： Manuel MERCE ,  Simon PONDAVEN ,  Philippe MARCHAND ,  Hervé VEZIN ,  Karima BEN TAYEB MEZIANE

IPC: G01N24/10

Abstract: This invention concerns a method for analysing the ageing stability of a bituminous binder, in particular by reference to its susceptibility to oxidation, by analysing a sample of the bituminous binder by means of electron spin resonance and measuring the integral of the signal of the carbon-centred stable radicals; accelerated ageing of the bituminous binder, comprising: i) heating the bituminous binder, followed by ii) heating the bituminous binder resulting from step i) under pressure; analysing a sample of the aged bituminous binder obtained from step b) by means of electron spin resonance and measuring the integral of the signal of the carbon-centred stable radicals; and comparing the integral of the signal of the carbon-centred stable radicals of the bituminous binder obtained from the first step and that obtained from the previous step.

公开(公告)号：US20210324049A1

公开(公告)日：2021-10-21

申请号：US17258891

申请日：2019-07-09

Applicant: INSERM (Institut National de La Santé et de la Recherche Médicale) ,  Institut Pasteur de Lille ,  Centre National de la Recherche Scientifique (CNRS) ,  Université de Lille

Inventor： Laurence COCQUEREL-DEPROY ,  Claire MONTPELLIER ,  Jean DUBUISSON

IPC: C07K16/10 ,  G01N33/576 ,  G01N33/535

Abstract: Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a non-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 542 to 555 of SEQ ID NO: 1.

公开(公告)号：US20210269510A1

公开(公告)日：2021-09-02

申请号：US17257966

申请日：2019-07-09

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCH MÉDICALE ,  INSTITUT PASTEUR DE LILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ DE LILLE

Inventor： Laurence COCQUEREL-DEPROY ,  Claire MONTPELLIER ,  Jean DUBUISSON

IPC: C07K16/10 ,  G01N33/576 ,  G01N33/558

Abstract: Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a quasi-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 10 to 23 of SEQ ID NO: 1.

公开(公告)号：US20210038545A1

公开(公告)日：2021-02-11

申请号：US16965663

申请日：2019-01-30

Applicant: NSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT PASTEUR DE LILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG ,  UNIVERSITÉ DE LILLE

Inventor： François TROTTEIN ,  Adeline BARTHELEMY ,  Valentin SENCIO ,  Mauro Martins TEIXEIRA ,  Angelica THOMAZ VIEIRA ,  Luciana TAVARES

IPC: A61K31/19 ,  A61P31/04 ,  G01N33/92

Abstract: Severe influenza is associated with defects in pulmonary innate immunity, a phenomenon leading to secondary bacterial infections. The gut microbiota can control immune/inflammatory responses locally and at distant sites. The inventors hypothesized that perturbation of the gut microbiota during severe influenza might participate in bacterial superinfection post-influenza. Their data demonstrated that influenza infection profoundly altered the functionality of the gut microbiota as assessed by the altered production of short chain fatty acids (SCFAs). Remarkably, treatment of colonized (IAV microbiota) mice or IAV-infected mice with acetate, the main SCFA found systematically, reinforced host defenses against S. pneumoniae. The present invention thus relates to the use of short-chain fatty acids for the treatment of bacterial superinfections post-influenza.

公开(公告)号：US20210017131A1

公开(公告)日：2021-01-21

申请号：US17042806

申请日：2019-03-29

Applicant: Centre national de la recherche scientifique ,  CHRU de Lille ,  Universite Côte D'Azur ,  Institut National de la Sante et da la Recherche Medicale (INSERM) ,  Université de Lille ,  YNCREA Hauts de France

Inventor： Valérie Vouret ,  Laetitia Douguet ,  Alina Ghinet ,  Germain Homerin ,  Benoît Guy Marie Rigo ,  Davy Jérémy Baudelet ,  Xavier Dezitter ,  Régis Millet ,  Christophe Furman

IPC: C07D207/16 ,  C07D401/12 ,  C07D409/12 ,  A61K39/395 ,  A61K31/4439 ,  A61K31/4025 ,  A61K31/4015 ,  A61P1/00 ,  A61P35/00

Abstract: The present invention relates to compounds of formula (I), their enantiomers and their pharmaceutically acceptable salts, and their use in therapy, particularly for the prevention and/or treatment of cancer or inflammatory diseases.

公开(公告)号：US10736937B2

公开(公告)日：2020-08-11

申请号：US15537596

申请日：2015-12-22

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 ,  UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES ,  INSTITUT PASTEUR DE LILLE

Inventor： Jean-Claude Sirard ,  Christophe Carnoy ,  François Trottein ,  Rémi Porte

IPC: A61K31/04 ,  A61K38/16 ,  A61P31/04 ,  A61K45/06

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza. In particular, the present invention relates to a method of treating a bacterial superinfection post-influenza in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide optionally in combination with at least one antibiotic.